Hopeful Warrior Blog Named Top Lymphoma Blog to Follow in 2021

Whether you’re navigating cancer, or caring for someone who is, blogs can be a valuable resource for support and information.

Feedspot recently selected the Hopeful Warrior Blog as one of the top lymphoma blogs to follow in 2021. The ranking was based on a variety of factors including relevancy, post frequency, social media engagement and more.

Top Lymphoma Blogs

 1. Lymphoma Action

Read the latest news and views from Lymphoma Action. Lymphoma Action is the UK's only charity dedicated to lymphoma, the fifth most common cancer. We've been providing in-depth, expert information for 35 years, helping thousands of people affected by lymphoma.

2. New Developments in Lymphoma

We bring the most promising new drugs and treatment approaches to people living with cancer, and our researchers have contributed to the development and FDA approval of nearly all of the recently available lymphoma therapies. Whether you are someone living with lymphoma, a family member or friend looking for more information, or a health care provider looking to refer a patient to a clinical trial, we hope our website will be a helpful resource.

3. The Hopeful Warrior Blog

 The Hopeful Warrior blog is a platform to support and raise awareness for those battling Lymphoma and other blood cancers. In addition to sharing the author’s personal experience with cancer, the Hopeful Warrior Blog also covers various psychological, spiritual, and motivational concepts and offers coping strategies tips for individuals and families fighting cancer.

4. Hodgkin's Lymphoma Awareness Ireland

This blog begins with the diagnoses leading to the stages and on to the therapy with remission, relapse and return to remission. The author and founder of this site Ian Doherty was diagnosed on the 14th of February 2014 with Stage 4B D5 Hodgkin's Lymphoma, he will be telling his story on this site as he continues his battle with Lymphoma.

5. Cancer Therapy Advisor - Lymphoma News

Non-Hodgkins and Hodgkins lymphoma news, research and treatment studies, clinical trials, and more for oncologists, and medical professionals.

Click here to learn more and see the complete list.

Research Provides Treatment Breakthroughs For Lymphoma

Blood cancers, including the main types leukemia, lymphoma and myeloma, are the third leading cause of cancer deaths in the United States, according to the Leukemia & Lymphoma Society. While there are no means of preventing or screening for most blood cancers, recent breakthroughs for lymphoma treatment are improving quality of life and survival.

Lymphomas are cancers of the lymphocytes, a type of white blood cell of the lymphatic system which play a key role in the body’s immune system. The two main types of lymphoma are Hodgkin lymphoma, in which there is a particular type of abnormal lymphocyte called a Reed-Sternberg cell in the lymph nodes, and non-Hodgkin lymphoma, in which there is an absence of Reed-Sternberg cells. There are many different subtypes of non-Hodgkin lymphoma that can be either slow or fast growing.

Treatment for Hodgkin and non-Hodgkin lymphoma depends on the type, stage and unique biological features of the cancer. In addition to existing chemotherapy and radiation, new treatment developments include targeted antibody therapies, immunotherapies, enzyme inhibitors, medications that slow tumor growth and gene therapies. In many cases, these new procedures offer substantial improvements over existing therapies because they are more effective, have fewer side effects and do not carry the same risks.

This year alone, the Food and Drug Administration approved two medications that significantly expand treatment options for lymphoma. The first is an immunotherapy drug called pembrolizumab, which can be used to treat for refractory Hodgkin lymphoma in children and adults who have been treated with at least three prior therapies. The second options is the enzyme inhibitor copanlisib which treats adults with relapsed follicular lymphoma, a type of slow-growing non-Hodgkin lymphoma, who have received at least two prior lines of systemic therapy.

Additionally, a chemotherapy-free treatment regimen for follicular lymphoma is showing promise in clinical trials and may provide a reasonable alternative to chemotherapy for some patients.

As treatment developments for lymphoma and other hematologic cancers continually advance, it's important to be diagnosed and treated at a comprehensive cancer center. NewYork-Presbyterian is leading groundbreaking research initiatives to enhance the diagnosis and treatment of lymphoma.

Read more...

Shut-off Switch for Lymphoma?

Safety switches that automatically stop the device for example before it overheats are built into many electrical appliances. Cells are also equipped with such "emergency stop" functions. They make sure that a defective cell doesn't become a tumor cell. A team from Technical University of Munich has now discovered such a switch in T cells. These results can help to find new therapies against T cell Non-Hodgkin's lymphoma triggered by defective immune cells.

Read more...

Combination Immunotherapy Shown to Be Effective Initial Treatment for Relapsed Hodgkin Lymphoma

Newswise — For many people with classical Hodgkin lymphoma, the disease is one of the most curable forms of cancer with standard chemotherapy or chemo plus radiotherapy. But for the 10 to 30 percent of patients whose cancer relapses, or doesn’t respond to initial therapy, secondary treatment often involves harsher chemotherapies followed by an autologous stem cell transplant, which uses a patient’s own stem cells.

Now, researchers led by Alex Herrera, M.D., assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation and a hematologist/oncologist, have found that a combination of two immunotherapy drugs — free of traditional chemotherapy — may be a more tolerable way for patients to fight the disease before a transplant.

"In our clinical trial, we studied a combination of two exciting new drugs — brentuximab vedotin and nivolumab — for treatment of relapsed or refractory Hodgkin lymphoma after the failure of frontline therapy and found that the combination was a safe, well-tolerated and highly effective bridge to transplantation,” said Herrera, who conducted the study with researchers from across the United States.

Read More...